Palisade Bio is developing PALI-2108, a gut-restricted PDE4 inhibitor targeting ulcerative colitis and Crohn’s disease. Phase 1 trials showed favorable safety, target engagement, and early clinical activity, indicating a potentially differentiated mechanism. With $132.6 million in cash, the company is funded through key Phase 2 efficacy results expected in 2027–2028, minimizing near-term dilution risk. If PALI-2108’s efficacy is confirmed in larger trials, it could achieve significant market value similar to other oral ulcerative colitis therapies that have reached multi-billion dollar acquisitions.
Lyft director Janey Whiteside sold 14,220 shares of the company's stock at a price of $17 per share. This transaction reflects a significant insider sale, which investors often watch as a signal of confidence or strategic portfolio management. The sa...
Advanced Micro Devices (AMD) reported a 50% year-over-year revenue increase to $11.54 billion in Q2 2026, with strong margins and a data center segment now accounting for 58% of revenue. Despite a 7-8% stock drop after earnings, fundamentals like a 5...
Genel Energy PLC has disclosed that a connected shareholder group now controls nearly a quarter (24.53%) of the company following its designation as a takeover target. Umit Tolga Bilgin is the largest individual in this concert party, holding 68.5 mi...
Entain PLC reported first-half earnings that exceeded Shore Capital's forecasts, with group EBITDA at £574 million versus an expected £535 million. The company's digital net gaming revenue grew 7%, accelerating from 5% in Q1, supported by strong perf...
LeMaitre Vascular's stock dropped 31% after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages, but underlying demand remains strong with 10% organic sales growth and record-high margins. The company's fastest...
